To the best of our knowledge, this is the first study evaluating the clinicopathological significance of various drug-sensitivity markers, including VEGFR2, STMN1, TUBB3, TS, Topo-II, and GRP78/BiP, in patients with surgically resected PPC. This evidence concerns the gene HSPA5 and primary peritoneal carcinoma.